Back to Results
First PageMeta Content
Health / Afamelanotide / Biology / Erythropoietic protoporphyria / Erythropoietic porphyria / Placebo / Peptide hormones / Medicine / Porphyrias


Document Date: 2012-04-19 14:38:18

Open Document

File Size: 115,69 KB

Share Result on Facebook

City

Zurich / San Francisco / Melbourne / /

Company

Erythropoietic Press / New England Journal / Clinuvel Pharmaceuticals Ltd / BioTechnologyNews.net / the Herald / Financial Review / /

Continent

Asia / Australia / Europe / /

Country

United States / Australia / New Zealand / /

/

Event

Product Issues / FDA Phase / /

/

IndustryTerm

pharmaceutical development / biopharmaceutical / counterfeit products / treatment of UVrelated skin disorders / illegal and untested chemical substances / illegal products / illegal chemical substances / pharmaceutical progress / pharmaceutical / media coverage / broader media / online sale / /

MedicalCondition

UVrelated skin disorders / erythropoietic porphyria / afamelanotide Erythropoietic Protoporphyria / erythropoietic protoporphyria / disorders / /

MedicalTreatment

radiation / /

Organization

Swiss Office / FDA / American Academy of Dermatology / /

Person

Philippe Wolgen / Welcome / /

/

Position

CEO / Life Science CEO Forum / /

Product

Zürich / illegal products / /

PublishedMedium

The Age / the Herald Sun / the New England Journal / The Australian / /

Region

New England / /

Technology

radiation / /

URL

www.clinuvel.com / /

SocialTag